Drug Profile

KIT 2014

Alternative Names: KIT-2014

Latest Information Update: 30 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kither Biotech
Class Antifibrotics; Peptides
Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cystic fibrosis
New Molecular Entity Yes

Highest Development Phases

Phase I Cystic fibrosis
Research Respiration disorders

Most Recent Events

16 Oct 2024 Phase-I clinical trials in Cystic fibrosis (In volunteers) in Australia (Inhalation) (NCT06659757)
31 Mar 2022 Pharmacodynamics data from a preclinical trials in cystic fibrosis released by Kither Biotech
31 Mar 2022 Kither Biotech plans a phase I/IIa trial for cystic fibrosis (Inhalation) in 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com